Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model.

doi:10.1111/cts.13086

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model.

Clinical and translational science - 1 Nov 2021

Taylor Zachary L, Thompson Lauren E, Bear Heather, Mizuno Tomoyuki, Vinks Alexander A, Ramsey Laura B

Abstract excerpt

Low-dose methotrexate (MTX) is a first-line therapy for the treatment of arthritis. However, there is considerable interindividual variability in MTX exposure following standard dosing. Polymorphisms in SLCO1B1 significantly effect MTX clearance, altering therapeutic response. One decreased function variant, rs4149056 (c.521T>C, Val174Ala), slows MTX clearance and in vitro uptake of MTX. This phenotype was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis

Share to Collagen

Share to Liver-Specific Organic Anion Transporter 1

Share to Methotrexate

Share to Mice, Knockout

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Source

Open in PubMed Open full text

Identifiers

PMID: 34121338
DOI: 10.1111/cts.13086
PMCID: PMC8604247

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model.PMID 34121338Read ↗

Association of SLCO 1B1 *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis PatientsSemantic proximity Read ↗

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.Semantic proximity Read ↗

Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma.Semantic proximity Read ↗

Factors Underlying Failure of Methotrexate Treatment in Rheumatoid Arthritis: Implications in Personalized CareSemantic proximity Read ↗

Relationship between SLCO1B1 polymorphisms and methotrexate intolerance in Mexican children with juvenile idiopathic arthritis.Semantic proximity Read ↗

A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial.Semantic proximity Read ↗

Association between SLCO1A2 genetic variation and methotrexate toxicity in human rheumatoid arthritis treatment.Semantic proximity Read ↗

SLCO1B1 variants as predictors of methotrexate-related toxicity in children with juvenile idiopathic arthritis.Semantic proximity Read ↗

Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.Semantic proximity Read ↗

Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Semantic proximity Read ↗

Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation.Semantic proximity Read ↗

<i>ABCB1</i>and<i>ABCC3</i>Gene Polymorphisms Are Associated with First-year Response to Methotrexate in Juvenile Idiopathic ArthritisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.